What Democrats’ Drug Pricing Plan Means for Consumers
The new drug pricing plan creates protections against out-of-pocket costs for seniors with Medicare Part D benefits and people who take insulin.
Medicare Part D
-
Read more: What Democrats’ Drug Pricing Plan Means for Consumers -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from November 2020.
-
Read more: The Promise and Pitfalls of Trump’s “Most Favored Nation” Approach to Drug Pricing The Promise and Pitfalls of Trump’s “Most Favored Nation” Approach to Drug Pricing
A recent executive order aimed at addressing ballooning pharmaceutical expenditures is ambitious in scope, but its impact remains to be seen.
-
Read more: Value-Based Reimbursement Can Decrease Spending on Medicare During COVID-19 Value-Based Reimbursement Can Decrease Spending on Medicare During COVID-19
A value-based Medicare system is not only beneficial, but also necessary to protect the elderly and chronically ill during the pandemic.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
By Ameet Sarpatwari, Charlie Lee, Frazer Tessema, and Aaron S. Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division.
